---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-107873"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:17:49.156464+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics Q3 net loss $13.3M; cash runway into mid-2027; key trial data readouts on track

## Summary
- Net loss of $13.3M ($0.31 per share) vs $11.2M ($0.50 per share) in Q3 2024.
- Cash, equivalents and investments $133.6M as of Sept 30, expected to fund operations into mid-2027.
- R&D expenses $9.6M, up $1.5M YoY driven by THRIVE-3 startup costs.
- ADVANCED-2 interim data from ~25 BCG-Unresponsive NMIBC patients expected 1Q 2026.
- STARBORN-1 interim update in pediatric LMs expected 4Q 2025; THRIVE-3 first patient dosing by year-end 2025.

## SEC filing metadata
- accession: 0001213900-25-107873
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/0001213900-25-107873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390025107873/ea0263183-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-107873
- JSON: https://secwatch.observer/filing/0001213900-25-107873.json
- Plain text: https://secwatch.observer/filing/0001213900-25-107873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.